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Abstract A plethora of reports suggest that copper (Cu)
homeostasis is disturbed in Alzheimer’s disease (AD). In
the present report we evaluated the efficacy of oral Cu
supplementation on CSF biomarkers for AD. In a pro-
spective, randomized, double-blind, placebo-controlled
phase 2 clinical trial (12 months long) patients with mild
AD received either Cu-(II)-orotate-dihydrate (verum
group; 8 mg Cu daily) or placebo (placebo group). The
primary outcome measures in CSF were Ab42, Tau and
Phospho-Tau. The clinical trial demonstrates that long-
term oral intake of 8 mg Cu can be excluded as a risk
factor for AD based on CSF biomarker analysis. Cu
intake had no effect on the progression of Tau and
Phospho-Tau levels in CSF. While Ab42 levels declined
by 30% in the placebo group (P = 0.001), they decreased
only by 10% (P = 0.04) in the verum group. Since
decreased CSF Ab42 is a diagnostic marker for AD, this
observation may indicate that Cu treatment had a positive
effect on a relevant AD biomarker. Using mini-mental
state examination (MMSE) and Alzheimer disease
assessment scale-cognitive subscale (ADAS-cog) we have
previously demonstrated that there are no Cu treatment
effects on cognitive performance, however. Finally, CSF
Ab42 levels declined significantly in both groups within
12 months supporting the notion that CSF Ab42 may be
valid not only for diagnostic but also for prognostic
purposes in AD.
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Introduction
One major pathological hallmark of Alzheimer’s disease
(AD) is the deposition of b-amyloid (Ab) plaques in the
brain. Ab peptides result from enzymatic processing of the
b-amyloid precursor protein (APP) by b- and c-secretases.
Since cerebrospinal fluid (CSF) is in direct contact with the
central nervous system (CNS), measurement of the CSF
concentration of Ab peptides has shown to represent one
biomarker, which—especially in combination with
increased Tau protein concentration in CSF—can improve
the safety of clinical AD diagnosis. The normal level of
Ab1-42 is regularly found decreased to about 50% in
patients with AD (Lewczuk et al. 2004; Wiltfang et al.
2001, 2002). Among other possible factors which require a
confirmation the most accepted explanation is the accu-
mulation of Ab in plaques leading to decreased Ab42
levels in the CSF of AD patients.
Potentially toxic Ab peptides are generated from the
copper-binding APP by two independent proteolytic events
(Bayer et al. 2001; Glenner and Wong 1984; Hesse et al.
1994; Kang et al. 1987). APP is actively involved in bal-
ancing Cu concentrations in cells. In APP-knock-out mice,
Cu levels were found increased in cerebral cortex and liver
(White et al. 1999), whereas overexpression of APP was
reported to result in significantly reduced Cu levels in brain
tissue of different APP transgenic mouse strains (Bayer
et al. 2003; Phinney et al. 2003) and in mice over-
expressing the C-terminal fragment of APP (and enhanced
Ab secretion) (Maynard et al. 2002).
The N-terminal Cu binding domain (CuBD-I) of APP
shows structural homology to the Cu binding domain of Cu
chaperons (Barnham et al. 2003) binding Cu with nanomolar
affinity (Hesse et al. 1994). A secondary CuBD-II appears in
Ab after its release from APP (Atwood et al. 2000), and Cu
application was reported to increase Ab aggregation in vitro
[reviewed in (Bush 2003)]. APP reduces Cu(II) to Cu(I),
leading to oxidative modification of APP (Multhaup et al.
1996), which is facilitated through the protein surface
localization of the binding site thus resembling so called
cytoplasmic Cu chaperones (Barnham et al. 2003).
In cell culture systems, Cu supplementation was found to
stimulate the non-amyloidogenic APP pathway thereby
suppressing the formation of b amyloid (Borchardt et al.
1999). More recently, APP was shown in yeast cells to have
a Cu efflux activity thereby explaining why APP over-
expressing mice have a reduced Cu level in their brains
(Bayer et al. 2003; Phinney et al. 2003; Treiber et al. 2004).
Earlier studies in animals have reported that elevated Cu is a
risk factor for developing the AD related pathology. Cherny
et al. (2001) showed that clioquinol, a Cu and Zn chelating
agent, can remove b-amyloid plaque pathology. However, it
was unclear how this effect worked, since the authors
reported an increase of soluble Cu and Zn levels in the brain
of treated mice. This apparently contradictory finding could
be explained by the finding that clioquinol mediates Cu
uptake by transporting Cu across cell membranes counter-
acting Cu efflux activities of APP (Treiber et al. 2004).
The observation that dietary Cu supplementation in a
transgenic mouse model for AD does not only increase
bioavailable brain Cu levels and restores superoxide dis-
mutase-1 (SOD-1) activity but also lowers Ab levels in the
brain and prevents premature death, supports the notion
that a disturbed Cu homeostasis may be associated with the
pathological process in AD (Bayer et al. 2003). Further-
more, increasing Cu levels by genetic means reduced Ab
plaque load and rescued the premature death of APP
transgenic mice (Phinney et al. 2003).
Normally, Cu contained in the food is taken up in the
stomach and then absorbed in the small intestine. About
30–50% of the Cu is absorbed. Cu is distributed from the
liver throughout the body and transported in the blood-
stream bound to ceruloplasmin. The liver is the most
important organ for Cu distribution and storage. Cu is
excreted via the biliary system. Usually, 2 mg of Cu per
day are taken with food. Ingestion of as much as 10 mg of
Cu per day is considered to be safe. The clinical reference
value for physiological Cu plasma concentrations is 65–
165 lg/dl [reviewed in (Kessler et al. 2005)]. In an earlier
report we could show a negative correlation between
plasma Cu and ADAS-cog score in AD patients, i.e. cog-
nitive performance in patients with Cu levels within the
lower third of the physiological range was worse than in
patients with higher Cu plasma levels (Pajonk et al. 2005).
In addition, AD patients fulfilling the criteria of CSF
diagnosis for AD (defined as at least two of three markers
[Ab42, Tau, Phospho-Tau] being out of the reference
range) had significantly lower blood Cu levels than AD
patients who fulfilled none or only one of these CSF cri-
teria (Kessler et al. 2006).
Taken together, this brought us to hypothesize that
restoring brain Cu homeostasis might have a beneficial
influence on the progression of AD. We speculated that oral
Cu supplementation may stabilize CSF biomarker param-
eters in AD patients. Thus, we monitored the progression of
the disease in AD patients by recording the changes in CSF
and plasma within 12 months in a prospective, randomized,
double-blind pilot phase 2 clinical trial.
Material and methods
Study population
Criteria for participation in the study included written
informed consent as well as caregiver consent, a diagnosis
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of probable AD by means of NINCDS–ADRDA criteria
(McKhann et al. 1984), a MMSE score of 20–25. All
patients received 5–10 mg donepezil daily. Patients with
severe and unstable somatic diseases and patients with
present or known history of alcohol, drug or medication
abuse were excluded. Patients taking drugs for coexistent
diseases were included except those taking psychotropic
drugs, ‘‘nootropics’’ or health food supplements. The trial
has been approved by the appropriate ethics committee
and has therefore been performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki.
Study design
The study had a monocentric, prospective, double-blind,
placebo-controlled, parallel-group randomized design. In
total 68 patients were recruited. Screening procedure
consisted of a medical history, physical examination,
psychometric tests, blood tests, MRT scan and diagnostic
lumbar puncture. After 1 year a second lumbar puncture
was obtained to monitor possible CSF changes. Patients
were randomly allocated either to placebo or to verum
(Cu orotate). The oral dosage of Cu orotate was
51.62 mg (corresponding to 8 mg Cu) once daily. To
maintain blinding, capsules containing Cu orotate and
placebo had identical shape and colour. The duration of
the study was 12 months. The study was registered at
http://www.clinicaltrials.gov with the identification num-
ber NCT00608946.
Outcome measures
The primary efficacy variables were the changes from the
baseline score in the CSF Ab42, Tau and Phospho-Tau
levels. Efficacy evaluations were performed at baseline and
after 12 months.
CSF sampling
CSF was drawn from patients by lumbar puncture in the
afternoon, sampled in polypropylene vials and centrifuged
(1,000g, 10 min, 4C). Aliquots of 250 ll were stored at
-80C. Freezing of samples was conducted by directly
cooling 250 ll of CSF in polypropylene tubes down to
-80C without an intermediate temperature stage. The
samples did not undergo additional freeze and thaw cycles.
Ab42, Tau and Phospho-Tau quantification by ELISA
CSF amyloid beta 1–42 (Ab42), CSF total Tau, and CSF
Tau phosphorylated at threonine-181 (Phospho-Tau)
were quantified using ELISA as recommended by the
manufacturer (Innogenetics, Gent, Belgium; carried out at
the Medizinisches Labor Bremen, Germany). CSF samples
for ELISA were analysed at different time points.
Urea gel electrophoresis for Ab 1–37, 1–38, 1–39,
1–40 and 1–42 quantification by Western blotting
CSF proteins were separated on 10% Bicine/Tris gels
containing 8 M urea (22), and Ab peptide species were
revealed by western blotting using antibody 1E8. Synthetic
Ab peptides of different size were run in parallel in the
same gel system and under the same conditions for the
identification and quantification of Ab peptides by densi-
tometry. Immunoreactive band intensities were quantified
with the Quantity One v4.1 software (Bio-Rad). All sam-
ples were run as duplicates and each gel carried a five-step
dilution series of a synthetic Ab peptide mix. Bands were
quantified relative to this dilution series. The inter- and
intra-assay coefficients were below 10%. Mean values
were used for subsequent calculations. The CSF samples
were analysed altogether at one time point.
Cu, Zn and ceruloplasmin in blood
Blood was collected to determine the level of Cu and, Zn
by using atomic absorption spectroscopy (AAS) and to
analyze ceruloplasmin by the nephelometric method (see
below). Blood samples were collected into metal-free tubes
that contained lithium heparin as an anti-coagulant. Con-
centrations of Cu were measured in lithium-heparin plasma
samples, utilizing flame AAS (PerkinElmer, AAnalyst
800). Samples were diluted with deionised water, and the
analysis was performed using standards prepared in glyc-
erol to approximate the viscosity characteristics of the
diluted samples. Standard atomic absorption conditions
were utilized for Cu (air acetylene, wave length 324.8 nm).
The between-day coefficient of variation (CV%) for Cu
assay was 4.24% (at 88 lg/dl), and the between-day
coefficient of variation (CV%) for Zn assay was 7.21% (at
317 lg/dl). Cu, Zn and ceruloplasmin samples were ana-
lysed immediately after collection.
Ceruloplasmin has been determined by immunochemi-
cal reaction utilizing the nephelometric method (Behring
Nephelometer BN II). Reagents and quality control sera
were provided by Dade Behring Company (Germany).
The results were evaluated by means of logit-log func-
tion. Samples containing particles were centrifuged prior
to testing. Plasma specimens were automatically diluted
1:20 with N Diluent. The analytical imprecision has
been determined as follows: intra-assay CV 1.4%, inter-
assay CV 1.8%. The expected reference range utilising
this method was between 0.2 and 0.6 g/l (P2.5–P97.5
percentile).
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Cu levels in CSF
Inductively coupled plasma mass spectrometry (ICP-MS):
for analysis of metal concentrations (Cu and Zn) in CSF,
samples were prepared by HNO3 closed-vessel microwave
digestion and diluted in Milli-Q water to a final concen-
tration of 6.5% HNO3 for analysis by ICP-MS. ICP-MS
was performed by using a HP4500 Series 300 ShieldTorch
system instrument (Agilent, Waldbronn, Germany) in
peak-hopping mode with spacing at 0.05 atomic mass
units, three points per peak, three scans per replicate, and
an integration time of 300 ms per point. The rate of plasma
flow was 15 l/min with an auxiliary flow of 1.0 l/min. The
replicative form power was 1.2 kW. The sample was
introduced by using a crossflow nebulizer at a flow rate of
1.02 l/min. The CSF samples were analysed at one time
point.
Safety measures
Standard adverse event reporting was conducted. Before
baseline, the Cu content in drinking water at the patients’
home was analyzed under standard conditions; concentra-
tion of Cu in drinking water must not exceed 2 mg/l. For
safety reasons, blood analyses (including especially plasma
Cu levels and liver enzymes) were performed at week 1, 2,
3 and 4 after baseline and at month 3, 6, 9 and 12.
Data analysis
For statistical analyses SPSS 15 for Windows was used.
Significance level was a = 0.05. All tests were two-tailed.
Demographic variables and data on the course of the disease
at screening time (t1) were compared between the verum
and the placebo group with one-way analysis of variance
Table 1 Demographic and clinical data of patients at screening time (t1) that have completed the clinical trial
Placebo Verum v2 df P
Gender (no. male; no. female) m.:12; f.: 21 m.: 17; f: 18 1.04 1 0.31
APOE: number of E4 alleles (0, 1, 2) 0: 9; 1: 13; 2: 2 0: 7; 1: 16; 2: 2 0.54 2 0.76
n Mean ± SEM n Mean ± SEM F df P
Age (years) 33 69.48 ± 1.39 35 70.37 ± 1.12 0.25 1, 66 0.62
Disease Duration (months) 33 24.73 ± 2.69 34 33.26 ± 4.97 2.25 1, 65 0.14
Age at onset (years) 33 67.48 ± 1.34 34 67.50 ± 1.09 0.00 1, 65 0.99
Education (years) 32 10.31 ± 0.35 34 11.41 ± 0.47 3.53 1, 64 0.065
CDT (score) 33 2.82 ± 0.23 34 2.88 ± 0.21 0.04 1, 65 0.84
MMSE (total score screening) 33 23.52 ± 0.52 35 24.17 ± 0.61 0.66 1, 66 0.42
The placebo and verum group did not differ significantly in any of the variables
m, Male; f, female; n, number of cases; m, mean; SEM, standard error of the mean; v2, v2 statistics; df, degrees of freedom; F, F statistics; CDT,
clock drawing test; MMSE, mini mental state examination
Table 2 Demographic and clinical data of patients with CSF collections at screening time (t1) at the beginning and at the end of the study
Placebo Verum v2 df P
Gender (no. male; no. female) m.:4; f.: 13 m.: 11; f: 7 5.04 1 0.025
APOE: number of E4 alleles (0, 1, 2) 0: 6; 1: 8; 2: 1 0: 2; 1: 12; 2: 2 3.10 2 0.21
n Mean ± SEM n Mean ± SEM F df P
Age (years) 17 67.76 ± 1.72 18 68.94 ± 1.67 0.24 1, 33 0.63
Disease Duration (months) 17 23.12 ± 3.79 18 31.50 ± 8.52 0.78 1, 33 0.38
Age at onset (years) 17 65.94 ± 1.72 18 66.44 ± 1.50 0.05 1, 33 0.83
Education (years) 17 10.59 ± 0.54 18 12.06 ± 0.67 2.86 1, 33 0.10
CDT (score) 17 2.76 ± 0.36 18 2.94 ± 0.27 0.16 1, 33 0.69
MMSE (total score screening) 17 23.71 ± 0.83 18 23.67 ± 0.95 0.00 1, 33 0.98
m, Male; f, female; n, number of cases; m, mean; SEM, standard error of the mean; v2, v2 statistics; df, degrees of freedom; F, F statistics; CDT,
clock drawing test; MMSE, mini mental state examination
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(ANOVA). v2 test on independence was used to analyze, if
the gender distribution was different between the two
groups and if the number of APOE E4 alleles differed
between the groups (Tables 1, 2). Primary dependent vari-
ables were ELISA Ab levels of Ab42, Tau and Phospho-
Tau. They were expressed as absolute numbers at the
starting point (t1) and 12 months later at the end of the study
(t12). Secondary dependent variables were: Western blot Ab
levels, expressed as % of total Ab: 1–42, 1–40, 1–39, 1–38,
1–37%, or as Ab ratios 1–42/1–40, 1–42/1–38, 1–38/1–40,
such as cholesterol, plasma Zn, ceruloplasmin, plasma Cu
and CSF Cu values, expressed as absolute numbers at t1
and t12. Independent between-subject factor was group
(placebo, verum), within-subject factor was time of mea-
surement. Kolmogorov–Smirnov tests were used to test, if
there were significant deviations of the dependent variables
from the normality assumption. At t1 (Table 3) and t12
(Table 4) one-way ANOVA with fixed factor group was
performed for the dependent variables and found to be
normal distributed. For the variables, where the normality
Table 3 Descriptive Statistics at screening time (t1), ANOVA/Mann-Whitney U test
Placebo Verum % Diff. verum versus placebo Factor group
n Mean ± SEM n Mean ± SEM df F P
WB: Ab 1–42% 11 4.6 ± 0.49 11 4.0 ± 0.39 -13.8 1, 20 1.0 0.3
WB: Ab 1–40% 11 66.0 ± 1.37 11 67.5 ± 0.80 2.1 1, 20 0.8 0.4
WB: Ab 1–39% 11 9.4 ± 0.60 11 9.4 ± 0.26 0.1 1, 20 0.0 1.0
WB: Ab 1–38% 11 13.1 ± 0.65 11 12.5 ± 0.44 -4.4 1, 20 0.6 0.5
WB: Ab 1–37% 11 6.8 ± 0.60 11 6.6 ± 0.32 -2.8 1, 20 0.1 0.8
WB: Ab 42/40 11 0.069 ± 0.01 11 0.059 ± 0.01 -15.0 1, 20 1.3 0.3
WB: Ab 42/38 11 0.375 ± 0.05 11 0.328 ± 0.03 -12.4 1, 20 0.5 0.5
WB: Ab 38/40 11 0.200 ± 0.01 11 0.186 ± 0.01 -7.1 1, 20 0.9 0.4
Cholesterol plasma (mg/dl) 20 211.0 ± 8.98 17 211.1 ± 9.52 0.1 1, 35 0.0 1.0
Zn plasma (lg/ml) 24 67.3 ± 1.61 26 65.9 ± 1.47 -2.0 1, 48 0.4 0.5
Ceruloplasmin plasma (mg/dl) 25 27.8 ± 1.07 29 27.0 ± 0.98 -2.8 1, 52 0.3 0.6
Cu plasma (lg/dl) 25 109.0 ± 4.68 27 98.5 ± 3.41 -9.6 1, 50 3.3 0.1
ANOVA and Mann–Whitney U test were used where appropriate and show no significant difference between the verum and placebo group
n, Sample size; m, mean; SEM, standard error of the mean; % Diff., difference verum versus placebo group in per cent terms; df, degrees of
freedom; F, F statistics; P, error probability for falsely rejecting the null hypothesis, that there are no mean differences between the two treatment
groups; WB, Western blot: % of total Ab
Table 4 Descriptive statistics at the end (t12), ANOVA/Mann–Whitney U test
Placebo Verum % Diff. verum versus placebo Factor group
n Mean ± SEM n Mean ± SEM df F P
WB: Ab 1–42% 11 4.38 ± 0.46 11 3.8 ± 0.36 -14.3 1, 20 1.2 0.3
WB: Ab 1–40% 11 65.9 ± 1.25 11 68.1 ± 1.02 3.2 1, 20 1.7 0.2
WB: Ab 1–39% 11 9.5 ± 0.56 11 9.1 ± 0.36 -4.3 1, 20 0.4 0.5
WB: Ab 1–38% 11 12.9 ± 0.58 11 12.5 ± 0.37 -3.6 1, 20 0.5 0.5
WB: Ab 1–37% 11 7.2 ± 0.65 11 6.6 ± 0.37 -8.5 1, 20 0.7 0.4
WB: Ab 42/40 11 0.066 ± 0.01 11 0.056 ± 0.01 -15.7 1, 20 1.4 0.3
WB: Ab 42/38 11 0.359 ± 0.05 11 0.301 ± 0.03 -16.1 1, 20 0.9 0.4
WB: Ab 38/40 11 0.198 ± 0.04 11 0.184 ± 0.03 -7.0 1, 20 1.0 0.3
Cholesterol plasma (mg/dl) 20 207.8 ± 7.46 17 211.3 ± 8.38 1.7 1, 35 0.1 0.8
Zn plasma (lg/ml) 24 67.2 ± 2.22 26 70.1 ± 2.19 4.4 1, 48 0.9 0.5
Ceruloplasmin plasma (mg/dl) 25 29.2 ± 0.97 29 27.8 ± 0.89 -4.6 1, 52 1.0 0.3
Cu plasma (lg/dl) 25 100.8 ± 4.32 27 100.7 ± 2.94 -0.1 1, 65 0.0 1.0
ANOVA and Mann–Whitney U test were used where appropriate and show no significant difference between the verum and placebo group
n, Sample size; m, mean; SEM, standard error of the mean; % Diff., difference verum versus placebo group in per cent terms; df, degrees of
freedom; F, F statistics; P, error probability for falsely rejecting the null hypothesis, that there are no mean differences between the two treatment
groups; WB, Western blot: % of total Ab
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assumption was rejected, non-parametric Mann–Whitney U
test with fixed factor group was computed. These analyses
were based on the patients that completed the examinations.
For Western blot and ELISA variables and CSF Cu it was
tested if the change over time (t12–t1) was gender related
[ANOVA (gender 9 group) or Mann–Whitney U test:
males versus females separately for placebo and verum
patients, respectively]. As main analysis the general linear
model procedure (GLM) was used to perform a multivariate
analysis of variance (MANOVA) with a repeated measure
design using the within-subject factor time of measurement
(t12 vs. t1) and the between-subject factor group if the
dependent variables were tested to be normal distributed. If
the normality assumption was rejected, the non-parametric
Wilcoxon test with the within-subject factor time (t12 vs. t1)
was done separately for the placebo and the verum group.
The change over time (t12–t1) of CSF copper values were
correlated with cholesterol and Ab42 differences (t12–t1)
using Spearman correlation coefficients.
Power calculation
The power calculation was based on the success criterion
of the medication having an effect on the primary efficacy
variables for CSF ELISA Ab42 levels applying a 5% sig-
nificance level for each analysis. Assuming a large effect
size of [(mverum - mplacebo)/r] = 1 (notations: mverum
mean change over time (t12–t1) in the verum group, mplacebo
mean change over time (t12–t1) in the placebo group, r
pooled standard deviation) and a sample size of 35 patients
(CSF Ab42: 18 in the verum group, 17 in the placebo
group), the study had a power of 83% to detect significant
differences between the groups.
Results
Subject recruitment and demographics
At t1, between the placebo and the verum group there were
no significant mean differences for age, disease duration,
age at onset of the disease, clock drawing test and mini
mental state examination at screening time. There was a
trend for a longer duration of education in the verum group
(F = 3.50; df = 1, 65; P = 0.066). The gender distribu-
tion was not significantly different between the verum and
the placebo group. The number of APOE E4 allele carriers
was not significantly different between the two groups
(Table 1). Table 2 shows the demographic data of those
patients with CSF samples at the beginning and the end of
the study. There were also no significant mean differences
for age, disease duration, age at onset of the disease,
clock drawing test and mini mental state examination at
screening time. However, the gender distribution was sig-
nificantly different with the number of male patients was
significantly higher in the verum group.
Proof of concept
Kolmogorov–Smirnov test showed that in the placebo
group and in the verum group as well, there were signifi-
cant deviations from the normal distribution for ELISA
Ab42, Tau and CSF Cu values. Consequently, for these
variables, non-parametric tests were used. For all other
dependent variables, the normality assumption could be
maintained, and thus, for further analysis, parametric tests
were performed. The change over time of all Western blot
and ELISA variables and of CSF Cu was not significantly
different between male versus female patients.
For most data there were no significant mean differences
between the placebo and the verum group at t1 (Table 3)
and at t12 (Table 4). There were significant effects of
within-subject factor time for Ab concentration detected by
Western blot 1–42% (t12 vs. t1 -5.9%; F = 5.7; df = 1,
20; P = 0.03), Ab ratio 1–42/1–40% (t12 vs. t1 -6.0%;
F = 5.1; df = 1, 20; P = 0.04), and ceruloplasmin % (t12
vs. t1 ?3.9%; F = 6.5; df = 1, 52; P = 0.01), however,
these changes over time were not group related, i.e., there
was no treatment effect using MANOVA with repeated
measures design. Furthermore, there was a significant
interaction of time and group for Cu in plasma (t12 vs. t1:
placebo -7.5%; verum ?2.3%; F = 5.2; df = 1, 50;
P = 0.03). For Cu in CSF there was a significant increase
in the placebo group (t12 vs. t1: ?211.6%; Z = -2.6;
P = 0.01), whereas there was only a trend for an increase
over time in the verum group (t12 vs. t1: ?52.9%; Z = -1.9;
P = 0.06).
There were no significant correlations for the change
over time (t12–t1) between cholesterol and Cu values in
plasma (placebo:q = 0.02; df = 17; P = 0.94; verum:
q = 0.21; df = 15; P = 0.42) as well as in CSF (placebo:
q = 0.33; df = 12; P = 0.25, verum: q = -0.15; df = 10;
P = 0.64).
In contrast to the other values CSF-Ab42, CSF-Tau and
CSF-Cu levels did not show a normal distribution, there-
fore non-parametric Wilcoxon tests were used to compare
time point t1 at the beginning and t12 at the end of study.
CSF Ab42 was significantly decreased in both Cu-treated
(P = 0.04) and placebo (P = 0.001) groups after
12 months. Of interest Ab42 levels deceased by 30% in the
placebo group, whereas only 10% in the Cu treated group,
which may be regarded as a mild treatment effect. No
significant effects were seen in Tau, P-Tau and Cu levels.
CSF Cu levels in the placebo group increased significantly
(P = 0.01) due to lower levels at the beginning, however,
there was no significant group effect. P-Tau levels were
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normal distributed therefore MANOVA analysis with
repeated measures design was used. Again, P-Tau levels
showed no significant differences (Fig. 1). There were no
significant correlations for the change over time (t12–t1)
between Cu values in CSF and cholesterol (placebo:q =
0.33; df = 12; P = 0.25, verum: q = -0.15; df = 10;
P = 0.64) as well as between CSF-Cu and CSF-Ab42
(placebo:q = 0.32; df = 10; P = 0.31, verum:q = -0.39;
df = 12; P = 0.16).
Discussion
APP and Ab are both metalloproteins which bind Cu in
vitro and were suggested to be involved in brain Cu
homeostasis. Maynard et al. (2002) have shown that
overexpression of the Ab sequence contained within a
carboxy-terminal fragment of APP elicits significantly
reduced Cu levels in transgenic mouse brain. This effect
might be further enhanced by the drastically reduced bio-
availability of Cu possibly due to the binding to plaque Ab
(Lovell et al. 1998).
The APP mediated Cu efflux activity observed in APP
overexpressing living cells best explained the intracellular
Cu deficiency and a subsequently reduced SOD-1 activity
(Bayer et al. 2003; Treiber et al. 2004). In addition, a
genetically 1.5-fold up-regulated Cu level was associated
with an increased survival of APP transgenic mice and
lowered endogenous murine Ab levels prior to detectable
Ab plaques formed by the human APP transgene (Phinney
et al. 2003). These observations led us conclude that
restoring brain Cu homeostasis might have a beneficial
influence on the progression of AD biomarkers. Thus, in
the present clinical trial we investigated potential beneficial
effects of oral intake of Cu-(II)-orotate-dihydrate (8 mg Cu
daily) in AD patients and CSF was collected at beginning
and at the end of the study after 12 months.
The treatment was generally well tolerated although
there was no clear-cut beneficial effect on CSF biomarker
levels in AD patients. One may speculate that Cu treatment
normalized Cu levels in plasma in the verum group by
enhanced uptake and transport and improved tissue
homeostasis. The plasma Cu levels declined only in the
placebo group during the 12-months period, however the
Fig. 1 CSF parameters before
and at the end of the clinical
study. Ab42, Tau and Cu CSF
levels did not elicit normal
distribution, therefore
nonparametric Wilcoxon tests
were used to compare time point
t1 at the beginning and t12 at the
end of study. a CSF Ab42 was
significantly decreased in both
Cu-treated (P = 0.04) and
placebo (P = 0.001) groups
after 12 months. Of interest
Ab42 levels deceased by 30% in
the placebo group, whereas only
by 10% in the Cu treated group.
b No significant effect was seen
in Tau levels. c CSF Cu levels
in the placebo group increased
significantly (P = 0.01) due to
lower levels at the beginning,
however, there was no
significant Cu-treatment effect.
d P-Tau levels showed no
significant differences. All
values represent mean and
SEM. Number of samples for
Ab42, Tau and P-Tau was 17 in
placebo and 18 in the verum
group. Number of samples for
Cu analysis in CSF was 13 in
the placebo and 14 in the verum
group
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placebo group had higher Cu levels at the beginning of the
study by accident. Cu levels in the verum group were
unchanged, which seems to be paradoxical. Previously, we
have reported that significantly lower levels of Cu in
plasma were found in those AD patients, who fulfilled the
criteria of CSF diagnosis for AD (Kessler et al. 2006). In
addition we demonstrated reduced Cu levels in plasma in
patients with higher ADAScog scores (making more mis-
takes in this neuropsychological test) (Pajonk et al. 2005).
Reduced CSF levels of the Ab42 in AD patients have
been found in numerous studies, with high sensitivity and
are commonly used for diagnostic evaluation [reviewed in
(Andreasen et al. 2003)]. We also observed that Ab42
levels were reduced using Western blot and ELISA tech-
niques after a 12 month observation period corroborating
these earlier studies. However we did not find a change in
Tau or Phospho-Tau levels over time. On the other side
FDG-PET, PIB-PET and fMRI may be more suitable as in
vivo pathological markers.
Recently, it has been demonstrated that CSF Cu levels
negatively correlate with Ab42 levels in AD patients (ele-
vated Cu and decreased Ab42) (Strozyk et al. 2007). In good
agreement with this report, we found that Cu treatment
apparently had a small effect on Ab42 levels. Ab42 declined
in both the verum and placebo groups over time however
much more dramatically with 30% in the placebo group
(P = 0.001). The Ab42 levels declined only by 10% in the
verum group (P = 0.04). In contrast to this observation Cu
treatment had no beneficial effect on cognitive abilities tes-
ted by MMSE and ADAS-cog in AD patients of the present
clinical phase II pilot study as already shown (Kessler et al.
2008). No effect on cognitive performance and a stabilizing
effect on CSF Ab42 levels is to be contradictory and there-
fore needs further and independent evaluations.
One animal study showed that treatment of 21-months-
old Tg2576 mice with clioquinol, a Cu, Zn chelator,
inhibited plaque formation and concomitantly increased
soluble brain Cu and Zn levels (Cherny et al. 2001).
Moreover, lowered insoluble Ab levels (by 49%) and
increased soluble Ab levels (by 50%) were accompanied
with elevated Cu levels (and Zn). This increase of Cu- and
Zn-ions might either be attributed to an inefficiency of the
chelator with its known weak affinities for Zn (K1 = 7.0)
and for Cu (K1 = 8.9) or even more likely, due to a
facilitated uptake in brain of clioquinol–Cu complexes.
The latter hypothesis has been experimentally confirmed in
a yeast system in vitro (Treiber et al. 2004).
When AD patients were treated with clioquinol, the
placebo group deteriorated faster than the clioquinol group
suggesting a beneficial effect upon clioquinol treatment
(Ritchie et al. 2003). In contrast, clioquinol treatment of
APP transgenic mice was associated with premature death,
which could be rescued by Cu supplementation (Scha¨fer
et al. 2007). At present there is no simple explanation for
these apparently contradictory results.
Sparks and Schreurs (2003) challenged rabbits with a
high-cholesterol diet and reported that the intake of minor
concentrations of Cu (0.12 mg/l) in the drinking water
impaired behavior and induced plaque-like structures in the
hippocampus and temporal lobe. These surprising findings
implied that tap water Cu concentration might influence
AD. In the present study we did not find any correlation
between plasma or CSF Cu and cholesterol levels.
Postmortem Cu levels in CNS of AD patients were
found decreased (Deibel et al. 1996) or unchanged (Loef-
fler et al. 1996). Controversial results have also been
published on the level of Cu in plasma and brain in AD
patients. Plasma Cu levels being within the normal range
(65–165 lg/dl) in AD patients are in good agreement with
an earlier study (Jeandel et al. 1989). However, other
studies suggest that elevated Cu levels might be a risk
factor for AD without providing a rationale (Squitti et al.
2002, 2003, 2004). These results are in contrast to the
present study, which might be explained by the fact that we
studied Cu levels in the same patients within a 12 months
period and can therefore better control for inter-individual
differences. Short-term high Cu intake has been reported
not to affect Cu status or functions related to Cu status,
only long-term high Cu intake can result in increases in
some parameters in young men (Turnlund et al. 2004).
The present clinical trial demonstrates that long-term
oral intake of 8 mg Cu [Cu-(II)-orotate-dihydrate] can be
excluded as a risk factor for AD based on CSF biomarker
analysis. In addition, Ab42 levels declined significantly
within 12 months in CSF indicating its value as a prognostic
biomarker in addition to its common use for diagnosing AD.
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